Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

1.800 +0.040 (+2.27%)

Delayed Quote Updated: 12:02 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

November 24, 2021

Gainers iSpecimen (NASDAQ:ISPC) shares in...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 24, 2021

Gainers Biofrontera (NASDAQ:BFRI) shares ...

Via Benzinga

40 Stocks Moving In Wednesday's Mid-Day Session ↗

November 24, 2021

Gainers Biofrontera Inc. (NASDAQ: BFRI) shares jumped 109.5% to $5.51 after Roth Capital initiated coverage on the stock with a Buy rating and a $20 price target. Longeveron Inc...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 24, 2021

Gainers Ocuphire Pharma (NASDAQ:OCUP) stock rose 78.73% to $6.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $107.6...

Via Benzinga

28 Stocks Moving in Wednesday's Pre-Market Session ↗

November 24, 2021

Gainers Engine Gaming and Media, Inc. (NASDAQ: GAME) rose 51% to $4.80 in pre-market trading after the company reported Q4 2021 and FY21 revenue was higher year over year....

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday ↗

November 24, 2021

We're starting the last day of this short holiday week with a dive into the biggest pre-market stock movers for Wednesday!

Via InvestorPlace

56 Biggest Movers From Yesterday ↗

November 24, 2021

Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 23, 2021

Gainers Biolase (NASDAQ:BIOL) shares incr...

Via Benzinga

Mid-Afternoon Market Update: Dow Surges 100 Points; Zoom Video Shares Plunge ↗

November 23, 2021

Toward the end of trading Tuesday, the Dow traded up 0.29% to 35,723.97 while the NASDAQ fell 1.28% to 15,651.92. The S&P also fell, dropping 0.27% to 4,670.49. The U.S. has...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

November 23, 2021

Gainers Pasithea Therapeutics (NASDAQ:KTTA

Via Benzinga

Mid-Day Market Update: Nasdaq Tumbles Over 200 Points; Pasithea Therapeutics Shares Surge ↗

November 23, 2021

Midway through trading Tuesday, the Dow traded down 0.19% to 35,550.02 while the NASDAQ fell 1.45% to 15,624.16. The S&P also fell, dropping 0.63% to 4,653.33. The U.S. has...

Via Benzinga

Topics Stocks

36 Stocks Moving In Tuesday's Mid-Day Session ↗

November 23, 2021

Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 216.6% to $7.00 after the company announced its subsidiary Pasithea Clinics has been approved to provide...

Via Benzinga

Mid-Morning Market Update: Markets Mostly Lower; Best Buy Posts Upbeat Q3 Earnings ↗

November 23, 2021

Following the market opening Tuesday, the Dow traded up 0.02% to 35,627.53 while the NASDAQ fell 0.58% to 15,762.28. The S&P also fell, dropping 0.14% to 4,676.49. The U.S....

Via Benzinga

Topics Stocks

Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial ↗

November 23, 2021

Aptevo Therapeutics Inc (NASDAQ: APVO) has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML). A high-...

Via Benzinga

Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia

November 23, 2021

SEATTLE, WA / ACCESSWIRE / November 23, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...

From Aptevo Therapeutics

Via AccessWire

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

November 18, 2021

Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular session. As of 12:30 EST, this security is trading at...

Via Benzinga

70 Biggest Movers From Yesterday ↗

November 16, 2021

Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The...

Via Benzinga

Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting

November 15, 2021

SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...

From Aptevo Therapeutics

Via AccessWire

Looking Into Aptevo Therapeutics's Return On Capital Employed ↗

November 12, 2021

According to data from Benzinga Pro, during Q3, Aptevo Therapeutics's (NASDAQ:APVO) reported sales totaled $3.10 million. Despite a 16.99% increase in earnings, the company posted...

Via Benzinga

Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights

November 12, 2021

SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...

From Aptevo Therapeutics

Via AccessWire

Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021

November 11, 2021

Data support Advancement into the Clinic LUND, SWEDEN, and SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") today announce...

From Aptevo Therapeutics

Via AccessWire

Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting

November 11, 2021

Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the...

From Aptevo Therapeutics

Via AccessWire

Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021

October 27, 2021

SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...

From Aptevo Therapeutics

Via AccessWire

Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436

October 26, 2021

SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...

From Aptevo Therapeutics

Via AccessWire

Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging

September 28, 2021

Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for...

From Aptevo Therapeutics

Via AccessWire

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

August 24, 2021

Gainers Regencell Bioscience (NASDAQ:RGC)...

Via Benzinga

Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome

August 17, 2021

- Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies - Data was...

From Aptevo Therapeutics

Via AccessWire

Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights

August 12, 2021

SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology...

From Aptevo Therapeutics

Via AccessWire

Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference

July 16, 2021

SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on...

From Aptevo Therapeutics

Via AccessWire

Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index

June 29, 2021

SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on...

From Aptevo Therapeutics

Via AccessWire

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.